Laura Riva

TL;DR: A screen of the ReFRAME library of approximately 12,000 known drugs for antiviral activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) identified several candidate compounds with suitable activities and pharmacological profiles, which could potentially expedite the deployment of therapies for coronav virus disease 2019 (COVID-19).

TL;DR: It is found that SARS-CoV-2 replication induces a delayed interferon (IFN) response in lung epithelial cells and that IRF-3, -5, and NF-kB/p65 are the key transcription factors regulating the IFN response during Sars-Cov-2 infection.

TL;DR: In this paper, the authors show that clofazimine-an anti-leprosy drug with a favorable safety profile-possesses inhibitory activity against several coronaviruses, and can antagonize the replication of SARS-CoV-2 and MERS-coV in a range of in vitro systems.

TL;DR: To identify therapeutics that can be repurposed as SARS-CoV-2 antivirals, a library of known drugs encompassing approximately 12,000 clinical-stage or FDA-approved small molecules is profiled, reporting the identification of 30 known drugs that inhibit viral replication.

TL;DR: In this article, the authors developed a medium-throughput drug-screening system and identified a small-molecule library of 34 of 430 protein kinase inhibitors that were capable of inhibiting the SARS-CoV-2 cytopathic effect in human epithelial cells.